PureTech Health plc (NASDAQ:PRTC) Short Interest Up 106.0% in November

PureTech Health plc (NASDAQ:PRTC) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 20,600 shares, a growth of 106.0% from the November 15th total of 10,000 shares. Based on an average daily volume of 6,100 shares, the short-interest ratio is currently 3.4 days.

Analyst Ratings Changes

A number of research analysts recently commented on PRTC shares. Leerink Partnrs raised shares of PureTech Health to a “strong-buy” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of PureTech Health in a research note on Monday, September 9th. They set an “outperform” rating and a $45.00 target price for the company.

Hedge Funds Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC purchased a new position in PureTech Health plc (NASDAQ:PRTC) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned about 1.26% of PureTech Health at the end of the most recent reporting period. 0.04% of the stock is owned by institutional investors and hedge funds.

PureTech Health Stock Performance

PRTC stock traded up $0.23 during mid-day trading on Thursday, hitting $22.28. The stock had a trading volume of 2,317 shares, compared to its average volume of 4,081. PureTech Health has a 1-year low of $17.33 and a 1-year high of $34.00. The company has a fifty day moving average of $21.15 and a 200 day moving average of $22.72.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.